Annamaria Kosztin MD, PhD

Associate Professor, Cardiologist, EP and HF specialist, Semmelweis University

[Jon Cunningham @JonWCunningham]

Thanks to hosts @DrMerkely & @KosztinMd for inviting me to speak at the Semmelweis University Symposium in Budapest on AI in cardiovascular care

Enjoyed speaking with members of the Hungarian cardiology community and global colleagues like @NirUrielMD

Photo @LuHenri8

[Valentina Kutyifa @VKutyifa]

Excellent session on risk prediction of SCD and #PROFIDEHRA at #esc25 @escardio

[Valentina Kutyifa @VKutyifa]

Great honor to give a talk at the 2nd Budapest International Arrhythmia Symposium and catching up with colleagues from Hungary @URMC_DeptMed

[Hungarian Working Group on Arrhythmias and Pacing @Hungarianeps]

Excited for Day 0 of #BIAS2024! Preparations are in full swing, and we can’t wait to dive into the latest breakthroughs in #EP . Stay tuned for insights, discussions, and collaborations that will shape the future! #EHRAjointsessions, @EHRAPresident
https://t.co/HYKf7d1iuy

[Muthu Vaduganathan @mvaduganathan]

🔥 A new therapeutic era in #HFpEF

#FINEARTSHF with definitive evidence supporting the role of the non-steroidal MRA finerenone at #ESCCongress

Now in @NEJM

https://t.co/iRGr1fQ2jM

[Annamaria Kosztin MD, PhD @KosztinMd]

Join us at BIAS 2024 in Budapest!
Connect with leading experts and don’t miss this opportunity to explore the latest research and treatment in EP.
#BIAS2024 #EPeeps

[Hungarian Working Group on Arrhythmias and Pacing @Hungarianeps]

2024 BIAS - BUDAPEST International Arrhythmia Specialists' Days are coming - 19-21/SEP - Budapest, Hungary

[Muthu Vaduganathan @mvaduganathan]

*Breaking* P3 #FINEARTSHF meets its primary endpoint (CVd+total HF events)!

Non-steroidal MRA finerenone "demonstrates definitive CV benefits" in HFmrEF & HFpEF

Looking forward to presenting full results at #ESCCongress alongside @scottdsolomon @PSJhund

https://t.co/RHM58WTYbq

[Muthu Vaduganathan @mvaduganathan]

🔥🔥 #FINEARTSHF has officially completed enrollment & event-driven follow-up!

#FINEARTSHF (n=6001) is the largest RCT of an MRA in patients with HF—primary results to be presented at an upcoming meeting

Check out initial publications to set the stage🧵

https://t.co/KcWYMvnw9K

[EHJ Editor-in-Chief @ehj_ed]

Eight reasons why lipoprotein(a) should be measured in everyone at least once in a lifetime. Read more in EHJ!
https://t.co/QhyNJnb3nm
#Lp(a) @escardio @ESC_Journals

[EHJ Editor-in-Chief @ehj_ed]

Lipid-lowering therapies may have a potential for venous thromboembolism prevention, particularly in high-intensity dosing and in combination therapy. Read more in #EHJ.
https://t.co/EuD5Ckv3O3
#lipid #thromboembolism #cardiotwitter @ESC_Journals @escardio

[EHJ Editor-in-Chief @ehj_ed]

EHJ issue 45 - 19 is online:

Insights on managing embolic strokes of undetermined source, device-detected atrial fibrillation, peripheral artery disease, and the intricate heart-brain connection!

https://t.co/Gq5djKORKB

@escardio @ESC_Journals #EHJ #cardiotwitter

[Annamaria Kosztin MD, PhD @KosztinMd]

@WilfriedMullens @MarcoMetra Congratulations @WilfriedMullens and Board members!!!

[PROFID EHRA Trial @PROFID_EU]

#PROFIDEHRA starts soon in Hungary and we had the great chance to present the trial to EP experts during the Annual Meeting of the Hungarian Society of Cardiology. Thank you Prof. Bela Merkely (@DrMerkely) and Dr. Annamaria Kosztin (@KosztinMd) for this very important opportunity

[Mikhail Kosiborod @MkosiborodMD]

🔥 of the press in the European Heart Journal: Semaglutide and Diuretic use in obesity-related HFpEF. Large effects of semaglutide on reducing loop diuretic use and dose in the STEP-HFPEF Program
@AndrewJSauer
@ankeetbhatt
@HFpEF
@KSharmaMD
@mvaduganathan
https://t.co/nHcwwnMqfu

[HFAPresident @HFA_President]

#HeartFailure2024
No worries, a nurse-led natriuresis guided decongestion is safe. Take it EASY-HF.

@EvelyneMeekers

[Prof Chris P Gale @cpgale3]

If you are interesting in being a European research site for the @PROFID_EU RCT then contact us:

[email protected]

The study is testing primary prevention ICD vs no ICD in post #heartattack patients with #heartfailure & LVEF ≤35% receiving OMT.

https://t.co/YkMbDoIM5L

[Annamaria Kosztin MD, PhD @KosztinMd]

@WilfriedMullens @PSJhund Well deserved Prof Mullens!

[Annamaria Kosztin MD, PhD @KosztinMd]

Thank you for the opportunity to be part of this innovative and excellent trial and event. Congratulations on the enormous work!

[PROFID EHRA Trial @PROFID_EU]

@Marieke_Bak @HorizionEU @ESCardioNews @EHRAPresident @dehn_christine @KosztinMd @Rlenarczyk @amancayork @yirui_qian

[NEJM @NEJM]

EMPACT-MI trial: Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo. https://t.co/VEqOxgczh7

#ACC24

[Wilfried Mullens @WilfriedMullens]

Tremendous joint effort to optimize device implementation and care in #heartfailure
https://t.co/e1HtAvNkd6 (1/3)

@HFA_President @MarcoMetra @JeroenDauw @AlexMebazaa @VDelgadoGarcia @kvernooy @kevin_damman @ARakisheva @GianluSava @MariannaAdamo1 @cardioceptor @m4ggiesimpson